Parkinson's Disease Test potential, BLSI

From: Bad Black Babes Movies 134
Date: November 02, 2009
Time: 03:22 PM

Comments

Best Friends Fucking

Comments

Stories http://bzn.brazzers.com/m/btis/232f/?t=64&nats=goodpoon:Revshare:bzn,0,0,0,133549 #43377

From: http://bzn.brazzers.com/m/btis/231f/?t=64&nats=goodpoon:Revshare:bzn,0,0,0,133548
Date: October 12, 2009
Time: 08:45 AM

Comments

Horny young does face fucking

From: Gina_Bitch_5664c_lightgreen
Date: October 12, 2009
Time: 01:03 AM

Comments

girl67481

Comments

Experts Available to Discuss Clinical Development of the First Objective Test for Parkinson's Disease June 28, 2000 10:16 AM Eastern Time BOSTON--(BW HealthWire)--June 28, 2000--

Video Footage Also Available; B-Roll Compellingly Illustrates Why The Imaging Agent Altropane(R) Could Soon Be The First Widely Available, Objective Diagnostic For Parkinson's Disease

There is no widely available, objective diagnostic test for Parkinson's Disease (PD), but hope is on the horizon. As described in the June 25, 2000 edition of the New York Times, researchers have demonstrated that the imaging agent Altropane detects even the earliest signs of PD by "lighting up" the relative loss of dopamine-releasing neurons in the brain.

Approximately 250,000 individuals per year visit a physician with new, undiagnosed movement disorders and are therefore candidates for an Altropane scan. Clinical diagnosis is wrong about 20% of the time, however, and accurate detection is especially difficult with younger people because symptoms that suggest PD may actually be associated with a completely different medical condition. A widely available, definitive diagnostic test could ensure the earliest possible medical intervention for people who have PD, and drastically reduce the number of people who are mistakenly diagnosed with the condition.

The company developing Altropane, Boston Life Sciences, reported in April that the agent was 98% accurate in a Phase II clinical trial in differentiating PD from normal individuals. The Company completed enrollment in its Phase III clinical trials in March 2000, and hopes to have Altropane on the market by next year. Altropane is the only diagnostic currently nearing the market in the U.S. for early detection of PD and is also currently in Phase II clinical trials for the diagnosis of Attention Deficit Hyperactivity Disorder.

-- Interview with Dr. Rob Licho, nuclear medicine physician, U. Mass Memorial Medical Center

-- Lab footage includes imaging technology and comparative brain scans (normal vs. PD)

To schedule interviews or to obtain b-roll footage please contact: Jim Weinrebe or Francesca Infantine, Schwartz Communications, 781-684-0770

CONTACT: Schwartz Communications Jim Weinrebe or Francesca Infantine 781-684-0770

Please Note: This discussion is open to all site visitors and is not regulated by Prohost. Information posted in the discussion should not be considered to be coming from Prohost Research.

Prohost is an independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm.

P R O H O S T O n l i n e
The Newsletter of Biotechnology Insight and Investment

Biotechnology Discussion